Anixa Biosciences Inc (ANIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $88.65M
Last updated: Nov 17, 2026 at 4:15 PM ET
Anixa Biosciences Inc (ANIX) Statistics
Anixa Biosciences (ANIX) has a market cap of $88.65M and an enterprise value of $87.25M. Its share count is up 5.25% from a year earlier.
Total Valuation
Enterprise value is 1.58% below the market cap, as cash exceeds debt.
| Market Cap | $88.65M |
|---|---|
| Enterprise Value | $87.25M |
| Latest price (Nov 17, 2026) | $2.55 |
Key Dates
The next earnings report is set for Jan 11, 2027, after the close.
| Next Earnings Date | Jan 11, 2027, after the close |
|---|---|
| Last Earnings Date | Sep 9, 2026 |
| Fiscal Year End | October |
Price Statistics
The stock is down 41.91% over 52 weeks and trades 11.15% below its 50-day average.
| Beta (1Y) | 1.50 |
|---|---|
| 52-Week Change | -41.91% |
| 1-Month Change | -4.49% |
| 3-Month Change | -25.66% |
| 6-Month Change | -7.61% |
| 5-Year Change | -34.59% |
| 10-Year Change | -50.87% |
| Total Return (1Y) | -41.91% |
| Total Return (3Y CAGR) | -4.74% |
| Total Return (5Y CAGR) | -8.39% |
| Return vs SPY (1Y) | -49.36% |
| Max Drawdown (1Y) | -54.98% |
| Max Drawdown (3Y) | -57.57% |
| Sharpe Ratio (1Y) | -0.71 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $2.87 |
| 200-Day Average | $2.96 |
| 52-Week Range | $2.32 to $5.46 |
| RSI (14 Days) | 37.6 |
| Average Volume (20 Days) | 199.49K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.54x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 8.54x |
|---|---|
| Quick Ratio | 8.54x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -72.34% over the last 12 months, against a 5-year average of -52.20%.
| Return on Equity (ROE) | -72.34% |
|---|---|
| Return on Assets (ROA) | -69.44% |
| ROE (5Y Average) | -52.20% |
| ROA (5Y Average) | -49.46% |
| ROIC (5Y Average) | -55.30% |
Scores
ANIX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$9.00K |
| Operating Income | -$10.98M |
| Pretax Income | -$10.47M |
| Net Income | -$10.47M |
| Reported EPS (TTM) | -$0.31 |
Trailing 12 months through Jul 31, 2026.
Balance Sheet
Shareholder equity funds 96.02% of the $15.07M in total assets.
| Cash and Equivalents | $1.40M |
|---|---|
| Total Debt | $0 |
| Net Cash | $1.40M |
| Net Cash Per Share | $0.04 |
| Working Capital | $13.17M |
| Shareholder Equity | $14.47M |
| Book Value Per Share | $0.42 |
| Total Assets | $15.07M |
| Total Liabilities | $1.87M |
Balance sheet as of Jul 31, 2026.
Cash Flow
| Operating Cash Flow | -$7.38M |
|---|---|
| FCF Per Share | -$0.21 |
| Depreciation and Amortization | $134.00K |
Trailing 12 months through Jul 31, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -22.76% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -22.76% |
Dividends and Yields
ANIX does not pay a dividend.
| Buyback Yield | -2.75% |
|---|---|
| Shareholder Yield | -2.75% |
Stock Splits
The last split was a 1-for-25 reverse split on Jun 26, 2015.
| Last Split Date | Jun 26, 2015 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ANIX
What is ANIX's market cap?
Anixa Biosciences has a market cap of $88.65M. Its enterprise value, which adds debt and subtracts cash, is $87.25M.
How many shares of ANIX are outstanding?
Anixa Biosciences has 34.18M shares outstanding. The count is up 5.25% from a year earlier.
Does ANIX pay a dividend?
No. Anixa Biosciences does not pay a dividend.
How much debt does ANIX have?
Anixa Biosciences has $0 of total debt and $1.40M of cash and equivalents, a net cash position of $1.40M.
ANIX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors